Relative risk (RR) (95 % confidence interval (CI)) | RR (95 % CI) excluding outlier study by Jubb et al. [64] | |
---|---|---|
Pooled SAE results in our review | 1.39 (0.78–2.47) | – |
Original pooled SAE results in Rutjes et al. [8] | ||
- All studies | 1.41 (1.02–1.97) | – |
- Sample restricted to “large, blinded trials” | 1.55 (1.07–2.24) | – |
Our approximated pooled SAE results (data imputed for studies in Rutjes et al. [8] with proprietary data) | ||
- All studies | 1.42 (1.01–1.99) | 1.26 (0.83–1.90) |
- Sample restricted to “large, blinded trials” | 1.54 (1.05–2.28) | 1.37 (0.83–2.26) |
Approximated pooled SAE results including omitted SAEs (two cases of myocardial infarction [54, 75], four cases of severe knee swelling [54], one case of cerebral hemorrhage [26], and one case of breast cancer [75]) | ||
- All studies | 1.37 (0.98–1.91) | 1.21 (0.82–1.80) |
- Sample restricted to “large, blinded trials” | 1.50 (1.03–2.19) | 1.32 (0.82–2.13) |
Approximated pooled SAE results excluding four cancer cases [73] | ||
- All studies | 1.36 (0.97–1.89) | 1.20 (0.81–1.77) |
- Sample restricted to “large, blinded trials” | 1.48 (1.02–2.16) | 1.30 (0.81–2.09) |
Approximated pooled SAE results including omitted non-cancer SAEs (two cases of myocardial infarction [54, 75], four cases of severe knee swelling [54], one case of cerebral hemorrhage [26]) and excluding four cancer cases [73] | ||
- All studies | 1.37 (0.98–1.91) | 1.21 (0.81–1.80) |
- Sample restricted to “large, blinded trials” | 1.50 (1.03–2.18) | 1.32 (0.82–2.12) |